Celldex Therapeutics (CLDX) 424B5 Prospectus supplement for primary offering

Exhibit 107

Calculation of Filing Fee Tables

424(b)(5)

(Form Type)

Celldex Therapeutics, Inc.

(Exact Name of Each Registrant as Specified in its Charter)

Table 1: Newly Registered and Carry Forward Securities

Security Type

Security Class Title

Fee Calculation or Carry Forward Rule

Amount Registered

Proposed Maximum Offering Price Per Unit

Maximum Aggregate Offering Price

Fee Rate

Amount of Registration Fee

Carry Forward Form Type

Carry Forward File Number

Carry Forward Initial Effective Date

Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward

Fees to Be Paid

Equity

Common Stock, par value $0.001 per share

Rule 457(r)

9,798,000

(2)

$

47.00

$

460,506,000

0.00014760

$

67,970.69

Fees Previously Paid

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

Carry Forward Securities

Carry Forward Securities

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

Total Offering Amounts

$

460,506,000

$

67,970.69

(1)

Total Fees Previously Paid

-

Total Fee Offsets

-

Net Fee Due

$

67,970.69

(1)	In accordance with Rules 456(b) and 457(r) under the Securities Act of 1933, as amended (the “Securities Act”), the registrant initially deferred payment of all of the registration fees for the Registration Statement on Form S-3 (Registration No. 333-275300), filed on November 3, 2023.
(2)	Includes 1,278,000 shares of common stock that the underwriters have an option to purchase.